Group 1 - The company has approved an external investment plan to acquire a 51.6667% stake in Harbin Jixianglong Biotechnology Co., Ltd. (Jixianglong) through a total investment of RMB 31 million [2][3] - The investment includes RMB 21 million for acquiring existing shares and RMB 10 million for subscribing to new registered capital, resulting in a total registered capital of RMB 1,135.55 million for Jixianglong [2] - Following the completion of the transaction, Jixianglong will become a subsidiary of the company and will be included in the consolidated financial statements [2][3] Group 2 - The company has successfully completed the necessary business registration changes and obtained the business license from the Harbin New Area Management Committee [3]

公告文件 证券代码：000989 证券简称： 九芝堂 公告编号：2025-075 九芝堂股份有限公司 九芝堂股份有限公司董事会 一、对外投资的基本情况 九芝堂股份有限公司（以下简称"公司"）第九届董事会第十一次会议审议通 过了《关于对外投资的议案》并签署相关协议，公司以人民币 21,000 万元受让 哈尔滨吉象隆生物技术有限公司（以下简称"吉象隆"）原股东冷国庆、哈尔滨 创新创业投资有限公司、东晶、张琪、李晨阳、肖明辉、朱德宝、郭健合计持有 的吉象隆已实缴注册资本 769.2435 万元（对应本次交易完成后 35%的标的公司 股权），并以人民币 10,000 万元认购吉象隆 366.3065 万元的新增注册资本（对应 本次交易完成后 16.6667%的标的公司股权）。前述交易方案完成后，公司将持有 吉象隆 51.6667%的股权，对应吉象隆 1,135.5500 万元注册资本。吉象隆将成为 公司的控股子公司，纳入公司合并报表范围。 具体内容详见公司于 2025 年 10 月 30 日披露的《九芝堂股份有限公司关于 对外投资的公告》（2025-069）。 二、对外投资的进展情况 吉象隆已于近日完成股权转让及增加 ...

Group 1 - The Chinese medicine sector experienced a decline of 0.83% on November 28, with Yue Wannianqing leading the drop [1] - The Shanghai Composite Index closed at 3888.6, up 0.34%, while the Shenzhen Component Index closed at 12984.08, up 0.85% [1] - Key stocks in the Chinese medicine sector showed mixed performance, with Tai Long Pharmaceutical rising by 5.37% to a closing price of 8.04 [1] Group 2 - Yue Wannianqing saw a significant drop of 13.71%, closing at 22.84, with a trading volume of 296,100 shares [2] - Other notable declines included Zhongsheng Pharmaceutical, which fell by 10.00% to 23.95, and Te Yi Pharmaceutical, which decreased by 6.41% to 14.01 [2] - The overall net capital flow in the Chinese medicine sector indicated a net outflow of 981 million yuan from main funds, while retail investors contributed a net inflow of 766 million yuan [2]

Group 1 - The company has received a notification from a shareholder, Li Zhengguo, regarding the pledge of part of his shares, which does not involve significant asset restructuring or performance compensation obligations [1] - As of November 26, 2025, the pledged shares held by the shareholder are detailed, including those resulting from his position as vice chairman and general manager, which are subject to lock-up [2] - The company will continue to monitor the situation and fulfill its information disclosure obligations in accordance with relevant laws and regulations [3] Group 2 - The company has provided a list of documents for reference, including the securities pledge and judicial freeze details from the China Securities Depository and Clearing Corporation [4] - The board of directors of the company issued this notification on November 28, 2025 [5]

Core Points - The company, JiuZhiTang, announced that it received a notification from its major shareholder, Li Zhenguo, regarding the pledge of part of his shares [2] - The pledged amount is 13,160,000 shares [2]

Group 1 - The core point of the article is that Jiuzhitang (SZ 000989) announced a significant share pledge by its major shareholder, Li Zhenguo, who has pledged 13.16 million shares, bringing the total pledged shares to 93.63 million, which is 57.83% of his holdings [1] - As of the announcement date, Jiuzhitang's market capitalization is 8 billion yuan [1] - The revenue composition for Jiuzhitang for the first half of 2025 shows that the pharmaceutical industry accounts for 97.17%, pharmaceutical commerce for 2.63%, and other businesses for 0.2% [1]

公告文件 证券代码：000989 证券简称： 九芝堂 公告编号：2025-074 九芝堂股份有限公司 | 股东 名称 | 是否为控股 股东或第一 大股东及其 | 本次质押 数量 | 占其所 持股份 比例 | 占公司 总股本 比例 | 是否 为限 售股 | 是否为 补充质 押 | 质押起始日 | 质押到 期日 | 质权人 | 质押用 途 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 一致行动人 | | | | | | | | | | | 李振 国 | 否 | 13,160,000 | 8.13% | 1.54% | 是 | 否 | 2025-11-26 | 双方办 理解除 质押手 | 浙商证券 股份有限 公司 | 融资 | | | | | | | | | | 续止 | | | | 合计 | - | 13,160,000 | 8.13% | 1.54% | - | - | - | - | - | - | 一、本次质押基本情况 上述质押股份未负担重大资产重组等业绩补偿义务。 二、股东股份累计质押基本情况 截至202 ...

湖南启元律师事务所 关于九芝堂股份有限公司 2025年第三次临时股东会的 法律意见书 1 致：九芝堂股份有限公司 湖南启元律师事务所（以下简称"本所"）接受九芝堂股份有限公司（以下简 称"公司"）的委托，指派本所律师出席了公司 2025 年第三次临时股东会（以下 简称"本次股东会"），对本次股东会的召集和召开程序、出席会议人员及召集人 的资格、表决程序和表决结果的合法有效性进行律师见证，并发表法律意见。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中 华人民共和国证券法》（以下简称"《证券法》"）等我国现行法律法规、规范性 文件以及《九芝堂股份有限公司章程》（以下简称"《公司章程》"）等有关规定 出具本法律意见书。 本所及本所律师声明如下： （一）本所律师根据本法律意见书出具日以前已经发生或者存在的事实，严 格履行了法定职责，遵循了勤勉尽责和诚实信用原则，进行了充分的核查验证， 保证本法律意见书所认定的事实真实、准确、完整，所发表的结论性意见合法、 准确，不存在虚假记载、误导性陈述或者重大遗漏，并承担相应法律责任。 （二）本所律师出具本法律意见书是基于公司已承诺所有提供给本所律师的 文件 ...

公告资料 证券代码：000989 证券简称：九芝堂 公告编号：2025-073 九芝堂股份有限公司 2025年第三次临时股东会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导 性陈述或者重大遗漏。 （2）网络投票时间：通过深圳证券交易所（以下简称"深交所"）交易系统 进行网络投票的具体时间为2025年11月26日9:15-9:25，9:30-11:30，13:00-15:00； 通过深圳证券交易所互联网投票系统投票的具体时间为 2025 年 11 月 26 日 9:15 至 15:00 的任意时间。 （3）召开方式：现场表决与网络投票相结合。 （4）现场会议召开地点：公司管理中心第一会议室（北京市朝阳区朝阳体 育中心东侧路甲 518 号 A 座）。 （5）召集人：公司董事会 （6）主持人：公司董事长王立峰先生 特别提示： 1、本次股东会未出现否决议案的情形。 2、本次股东会未涉及变更以往股东会已通过的决议。 一、会议召开和出席情况 1、会议召开情况 （1）现场会议召开时间：2025 年 11 月 26 日 14:30 会议召开符合有关法律、行政法规、部门规章、规范性文件和 ...

Group 1 - The core viewpoint of the articles emphasizes that health is becoming a fundamental aspect of consumer behavior, shifting from reactive to proactive consumption, and integrating health into daily life [1][4][18] - The health consumption trend is particularly driven by women aged 20 to 40, who are the primary decision-makers for family health expenditures and are increasingly focused on self-care and emotional well-being [2][9] - There is a notable shift in health product categories from general functional items to more specific needs, such as menstrual care, emotional relief, and skin barrier repair, reflecting a more nuanced understanding of consumer demands [2][3][5] Group 2 - The integration of medical standards into everyday products is becoming more accepted, with consumers seeking higher safety and efficacy in items like medical-grade masks and oral solutions [3][15] - Brands are responding to the demand for convenience and efficiency, as seen in the transformation of traditional products like 九芝堂's herbal remedies into easy-to-consume formats [6][8] - New brands like beU are successfully addressing previously overlooked female needs in the market, demonstrating the importance of understanding specific consumer experiences and preferences [9][10][12] Group 3 - The health consumption landscape is evolving from a focus on disease prevention to enhancing overall quality of life, indicating a significant shift in consumer expectations [4][17] - The success of brands during events like Double 11 highlights the importance of precise demand identification and the ability to adapt offerings to meet specific consumer scenarios [5][17] - Platforms like Tmall Health are crucial in supporting new brands and products by providing exposure and incentives, thereby facilitating the growth of innovative health solutions [17][18]